HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methotrexate in the chemotherapy of lung cancer.

Abstract
Methotrexate (MTX) is an active agent in both non-small cell and small cell anaplastic lung cancer. A 26% partial response rate was obtained in 27 previously untreated patients with squamous cell bronchogenic tumors treated with 24-hour infusions of MTX at 400 mg/m2. Responses were seen predominantly in extrathoracic sites. In 38 evaluable patients with small cell carcinomas, 24-hour infusions of MTX at 200 mg/m2 in combination with cyclophosphamide and CCNU produced a 43% complete remission (CR) rate for a median survival of 62 weeks. Fifty-six percent of the CR's were seen in patients with extensive disease.
AuthorsJ F Smyth, H T Ford
JournalCancer treatment reports (Cancer Treat Rep) Vol. 65 Suppl 1 Pg. 161-3 ( 1981) ISSN: 0361-5960 [Print] United States
PMID6275986 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Lomustine
  • Cyclophosphamide
  • Methotrexate
Topics
  • Brain Neoplasms (secondary)
  • Carcinoma, Bronchogenic (drug therapy, mortality, radiotherapy)
  • Carcinoma, Small Cell (drug therapy, mortality, radiotherapy)
  • Carcinoma, Squamous Cell (drug therapy, mortality, radiotherapy)
  • Cyclophosphamide (administration & dosage)
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Infusions, Parenteral
  • Lomustine (administration & dosage)
  • Lung Neoplasms (drug therapy, radiotherapy)
  • Methotrexate (administration & dosage)
  • Neoplasm Recurrence, Local

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: